Do not let an interview recycle shortage-era assumptions. FDA’s April 1, 2026 clarification states that semaglutide and tirzepatide are not on its shortage list or 503B bulks list. Its shortage database should be checked again for the exact product at the decision date. (fda.gov)
Three additional developments deserve specific questions:
- Individualised documentation: In a September 18, 2026 warning letter to Empower Pharmacy, FDA questioned repeated significant-difference statements and technology workflows offering preselected statements. This is evidence of the agency’s stated enforcement concerns, not a substitute for reviewing the recipient’s response or subsequent proceedings. (fda.gov)
- 503B bulk substances: FDA announced a proposal on April 30, 2026 not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list. The announcement describes a proposal, not a final determination; this research did not establish a subsequent final disposition. (fda.gov)
- DSCSA timing: FDA’s August 6, 2026 letter grants qualifying small business dispensers specified exemptions for November 27, 2026 through November 27, 2027. It is not an exemption from every DSCSA obligation, and the new period begins after this document’s review date. (fda.gov)
Verification boundary: This document does not certify the current procedural status of every relevant lawsuit. Ask counsel to identify any operative order affecting the actual arrangement, rather than relying on a supplier’s reference to pending litigation.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- fda.gov · Source 2 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026
- fda.gov · Source 3 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- fda.gov · Source 4 ↗https://www.fda.gov/media/194424/download